LivaNova PLC
NASDAQ:LIVN

Watchlist Manager
LivaNova PLC Logo
LivaNova PLC
NASDAQ:LIVN
Watchlist
Price: 51.32 USD -0.74% Market Closed
Market Cap: 2.8B USD
Have any thoughts about
LivaNova PLC?
Write Note

LivaNova PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LivaNova PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
LivaNova PLC
NASDAQ:LIVN
Total Equity
$1.3B
CAGR 3-Years
0%
CAGR 5-Years
-3%
CAGR 10-Years
17%
Smith & Nephew PLC
LSE:SN
Total Equity
$5.2B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Total Equity
ÂŁ68.8m
CAGR 3-Years
-7%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Angle PLC
LSE:AGL
Total Equity
ÂŁ24.5m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Total Equity
ÂŁ47.4m
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Total Equity
$20.4m
CAGR 3-Years
63%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

LivaNova PLC
Glance View

Market Cap
2.8B USD
Industry
Health Care

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

LIVN Intrinsic Value
81.64 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is LivaNova PLC's Total Equity?
Total Equity
1.3B USD

Based on the financial report for Sep 30, 2024, LivaNova PLC's Total Equity amounts to 1.3B USD.

What is LivaNova PLC's Total Equity growth rate?
Total Equity CAGR 10Y
17%

Over the last year, the Total Equity growth was 7%.

Back to Top